Literature DB >> 36131147

Long-Term Efficacy and Recurrence Prediction of Prostatic Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Zhong-Wei Xu1, Chun-Gao Zhou1, Wei Tian1, Hai-Bin Shi1, Sheng Liu2.   

Abstract

PURPOSE: To explore the efficacy of prostatic artery embolization (PAE) for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) during long-term follow-up and analyze predictors related to LUTS recurrence.
METHODS: This was a single-center retrospective study involving 125 BPH patients with LUTS who underwent PAE from February 2014 to February 2020. The median follow-up was 36 months. Clinical success was defined as reductions in the International Prostate Symptom Score (IPSS) and quality of life (QoL) score and no need for any other treatment for LUTS; otherwise, it was regarded as a clinical failure. Recurrence was defined as a clinical failure that occurred after an initial success. Cumulative clinical success rates, recurrence rates and re-intervention rates were evaluated. Friedman test was performed to compare differences in IPSS, QoL and prostatic volume (PV) among baseline and follow-up times. Predictors for LUTS recurrence were analyzed with the univariate and multivariate Cox regression model.
RESULTS: Technical success (bilateral PAE) rate was 92.8% (116/125). Significant differences in IPSS, QoL and PV were observed between baseline and follow-up time points (P < 0.001). The cumulative clinical success rates at 2, 3, 4 and 5 years were 82.4%, 65.5%, 52.4% and 37.4%. The cumulative recurrence rates and re-intervention rates at 1, 2 and 5 years were 6.8%, 12.7%, 60.4% and 5.9%, 10.2%, 50.8%, respectively. Unilateral PAE was an significant predictor of recurrence (P < 0.05).
CONCLUSIONS: PAE is an effective treatment option for LUTS. Unilateral PAE is a significant independent predictor of LUTS recurrence.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Entities:  

Keywords:  Benign prostatic hyperplasia; Follow-up; Lower urinary tract symptoms; Prostatic artery embolization; Recurrence

Year:  2022        PMID: 36131147     DOI: 10.1007/s00270-022-03272-2

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.797


  18 in total

1.  Prostatic Artery Embolization Using 100-300-μm Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up.

Authors:  Raj Ayyagari; Taylor Powell; Lawrence Staib; Julius Chapiro; Anusha Raja; Shivank Bhatia; Toby Chai; Steven Schoenberger; Ralph Devito
Journal:  J Vasc Interv Radiol       Date:  2019-11-23       Impact factor: 3.464

2.  Medium- and Long-Term Outcome of Prostate Artery Embolization for Patients with Benign Prostatic Hyperplasia: Results in 630 Patients.

Authors:  João M Pisco; Tiago Bilhim; Luis C Pinheiro; Lucia Fernandes; Jose Pereira; Nuno V Costa; Marisa Duarte; António G Oliveira
Journal:  J Vasc Interv Radiol       Date:  2016-06-16       Impact factor: 3.464

3.  Four-Year Impact of Voiding and Storage Symptoms in Patients with Benign Prostatic Hyperplasia Treated with Prostatic Artery Embolization.

Authors:  Yen-Ting Lin; Héléna Pereira; Olivier Pellerin; Carole Déan; Nicolas Thiounn; Marc Sapoval
Journal:  J Vasc Interv Radiol       Date:  2020-02-24       Impact factor: 3.464

4.  Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study.

Authors:  Riad Salem; John Hairston; Elias Hohlastos; Ahsun Riaz; Joseph Kallini; Ahmed Gabr; Rehan Ali; Kimberly Jenkins; Jennifer Karp; Kush Desai; Bartley Thornburg; David Casalino; Frank Miller; Matthias Hofer; Nabeel Hamoui; Samdeep Mouli
Journal:  Urology       Date:  2018-07-20       Impact factor: 2.649

5.  Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up.

Authors:  Joao Martins Pisco; Hugo Rio Tinto; Luís Campos Pinheiro; Tiago Bilhim; Marisa Duarte; Lúcia Fernandes; José Pereira; António G Oliveira
Journal:  Eur Radiol       Date:  2013-01-31       Impact factor: 5.315

6.  Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: 10 Years' Experience.

Authors:  Francisco Cesar Carnevale; Airton Mota Moreira; Andre Moreira de Assis; Alberto Azoubel Antunes; Vanessa Cristina de Paula Rodrigues; Miguel Srougi; Giovanni Guido Cerri
Journal:  Radiology       Date:  2020-06-02       Impact factor: 11.105

7.  Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study).

Authors:  Alistair F Ray; John Powell; Mark J Speakman; Nicholas T Longford; Ranan DasGupta; Timothy Bryant; Sachin Modi; Jonathan Dyer; Mark Harris; Grace Carolan-Rees; Nigel Hacking
Journal:  BJU Int       Date:  2018-05-06       Impact factor: 5.588

8.  Prostate artery embolization has long term efficacy for treatment of severe lower urinary tract symptoms from giant prostatic hyperplasia.

Authors:  Alexander S Somwaru; Stephen Metting; Laura M Flisnik; Michael G Nellamattathil; Arjun Sharma; Venkat S Katabathina
Journal:  BMC Urol       Date:  2020-10-08       Impact factor: 2.264

9.  Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial.

Authors:  Dominik Abt; Gautier Müllhaupt; Lukas Hechelhammer; Stefan Markart; Sabine Güsewell; Hans-Peter Schmid; Livio Mordasini; Daniel S Engeler
Journal:  Eur Urol       Date:  2021-02-19       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.